Jianxing Huang

This inventor holds 13 USPTO granted patents and 2 published patent applications, plus 4 CIPO patents and 4 EPO patents. Top assignees: Agenebio, Inc., Agennix USA Inc.. Active years: 2010-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jianxing Huang. Retrieved from https://idiyas.com/inventor/jianxing-huang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 (Patent Applications = 2)

% Patents Active = 69.2

CIPO Patents = 4 (Patent Applications = 3)

EPO Patents = 4 (Patent Applications = 6)

Average Co-Inventor Count = 4.2

ph-index = 3

Forward Citations = 24(Granted Patents)

Location History:

N. Billerica, MA (US) (2010 - 2011)
Bedford, MA (US) (2012)
Bethlehem, PA (US) (2019 - 2024)

Company Filing History:

Years Active: 2010-2026

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12760030 - Benzazepine derivatives, compositions, and methods for treating cognitive impairment (2026-10-13),

2. 12528819 - Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment (2026-01-20),

3. 12291535 - Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment (2025-05-06),

4. 12024525 - Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment (2024-07-02),

5. 11505555 - Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment (2022-11-22),

6. 11414425 - Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment (2022-08-16),

7. 11312721 - Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment (2022-04-26),

8. 11142529 - Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment (2021-10-12),

9. 10815242 - Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment (2020-10-27),

10. 10329301 - Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment (2019-06-25),

11. 8097619 - Inhibitors of cyclin-dependent kinases, compositions and uses related thereto (2012-01-17),

12. 7893057 - Inhibitors of cyclin-dependent kinases, compositions and uses related thereto (2011-02-22),

13. 7786112 - Inhibitors of cyclin-dependent kinases, compositions and uses related thereto (2010-08-31),

Title: Innovations of Jianxing Huang in Cognitive Impairment Treatment

Introduction

Jianxing Huang is a notable inventor based in Bethlehem, PA (US), recognized for his contributions to the field of cognitive impairment treatment. With a total of 13 patents, Huang has made significant strides in developing therapeutic solutions for various central nervous system (CNS) disorders.

Latest Patents

Huang's latest patents focus on benzodiazepine derivatives, compositions, and methods for treating cognitive impairment. These inventions relate to the use of α5-containing GABAreceptor agonists, which are designed to treat cognitive impairment associated with CNS disorders. His work addresses a range of conditions, including age-related cognitive impairment, Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD), and various mental health disorders. The innovative approaches he has developed aim to improve the quality of life for individuals suffering from these debilitating conditions.

Career Highlights

Throughout his career, Huang has worked with several companies, including Agenebio, Inc. and Agennix USA Inc. His experience in these organizations has contributed to his expertise in the field of cognitive health and therapeutic development.

Collaborations

Huang has collaborated with notable colleagues such as Belew Mekonnen and John Anthony Butera. These partnerships have further enhanced his research and innovation capabilities, leading to advancements in treatment methodologies.

Conclusion

Jianxing Huang's work in the realm of cognitive impairment treatment showcases his dedication to improving therapeutic options for individuals affected by CNS disorders. His innovative patents and collaborations highlight the importance of continued research in this critical area of health.

Profile summary based on public USPTO records.